European urology最新文献

{"title":"Re: Propensity-matched Analysis of Open Versus Robotic Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II Testicular Cancer","authors":"Alireza Ghoreifi , James Porter , Hooman Djaladat","doi":"10.1016/j.eururo.2024.07.012","DOIUrl":"10.1016/j.eururo.2024.07.012","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages 91-92"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141880019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Metastasis and Recurrence Patterns in the Molecular Subtypes of Urothelial Bladder Cancer","authors":"Eva Compérat, Gabriel Wasinger, Johannes Kläger","doi":"10.1016/j.eururo.2024.08.002","DOIUrl":"10.1016/j.eururo.2024.08.002","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages 94-95"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study","authors":"Giuseppe Di Lorenzo , Carlo Buonerba","doi":"10.1016/j.eururo.2024.07.017","DOIUrl":"10.1016/j.eururo.2024.07.017","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages 92-93"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141880018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Aravindh Rathinam, Jonathan Katz, Robert Marcovich, and Hemendra N. Shah’s Letter to the Editor re: Michael Baboudjian, Hashim Hashim, Nikita Bhatt, et al. Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol 2024;86:213–20","authors":"Michael Baboudjian, Massimiliano Creta, Hashim Hashim, Vasileios Sakalis, Jean-Nicolas Cornu","doi":"10.1016/j.eururo.2024.12.004","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.12.004","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"9 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142888235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testicular Germ Cell Tumor Etiology: Still a Black Box?","authors":"Arnout R. Alberts, Marij Dinkelman-Smit, Tahlita C.M. Zuiverloon, Joost L. Boormans","doi":"10.1016/j.eururo.2024.11.024","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.024","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"2017 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142888099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Financial Burden of Localized and Metastatic Bladder Cancer","authors":"Pietro Scilipoti, Marco Moschini, Roger Li, Seth P. Lerner, Peter C. Black, Andrea Necchi, Morgan Rouprêt, Shahrokh F. Shariat, Shilpa Gupta, Alicia K. Morgans, Sarah P. Psutka, Ashish M. Kamat","doi":"10.1016/j.eururo.2024.12.002","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.12.002","url":null,"abstract":"<h3>Background and objective</h3>Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. Understanding these financial implications is crucial for effective resource allocation and optimization of treatment cost effectiveness. Here, we aim to systematically review and analyze the financial burden of BCa from the health care and patient perspectives.<h3>Methods</h3>A Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-compliant systematic review was conducted, searching PubMed/Medline, Embase, and public sources for studies evaluating the financial impact of BCa, encompassing costs, cost effectiveness, and financial toxicity (FT).<h3>Key findings and limitations</h3>Non–muscle-invasive BCa (NMIBC) incurs significant costs for surveillance and treatment, with costs exceeding $200 000 after 5 yr for high-risk NMIBC patients progressing after bacillus Calmette-Guerin (BCG) treatment (including inpatient, outpatient, and physician service expenses). Muscle-invasive BCa generates substantial costs from radical cystectomy (RC) and neoadjuvant chemotherapy, averaging $30 000–40 000 from surgical costs of RC, with additional expenses in case of complications. Trimodal therapy has higher costs (1-yr management cost &gt;$200 000) than RC because of higher outpatient, radiology, and medication costs. Metastatic BCa incurs the highest financial burden, with systemic therapy costs ranging from $40 000 to over $100 000 per five-cycle course, increasing further with combination therapies (ie, enfortumab vedotin and pembrolizumab), treatment-related toxicity, and supportive care. FT is particularly prevalent among younger, less educated, and minority populations.<h3>Conclusions and clinical implications</h3>BCa treatment, particularly in advanced stages, imposes a substantial economic burden. Innovations in care, while improving oncologic outcomes, necessitate detailed cost-effectiveness assessments. Addressing these economic challenges is essential for optimizing BCa management, targeting patients at a higher risk of FT, and improving patient quality of life.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"152 3-4 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142888100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Michael Baboudjian, Hashim Hashim, Nikita Bhatt, et al. Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol 2024;86:213–20","authors":"Aravindh Rathinam, Jonathan Katz, Robert Marcovich, Hemendra N. Shah","doi":"10.1016/j.eururo.2024.11.028","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.028","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142884106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy","authors":"Vadim S. Koshkin, Pongwut Danchaivijitr, Woo Kyun Bae, Andrey Semenov, Ozgur Ozyilkan, Yu-Li Su, José A. Arranz Arija, Masao Tsujihata, Martin Bögemann, Mathijs P. Hendriks, Silvia Neciosup Delgado, Eli Rosenbaum, Karla Alejandra Lopez, Abhishek Bavle, Chih-Chin Liu, Kentaro Imai, Andrea Furka","doi":"10.1016/j.eururo.2024.11.012","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.012","url":null,"abstract":"Patients with metastatic solid tumors who previously had stable disease or a response with immunotherapy may derive benefit from immunotherapy retreatment. This post hoc analysis evaluated pembrolizumab retreatment in patients with advanced/metastatic urothelial carcinoma who received pembrolizumab in KEYNOTE-045, KEYNOTE-052, or KEYNOTE-361, and either stopped pembrolizumab after a complete response (CR) or completed pembrolizumab (35 cycles [∼2 yr]) with an objective response or stable disease. Upon disease progression, protocol-specified pembrolizumab retreatment (200 mg intravenously every 3 wk) was administered for ≤17 cycles. Forty-nine patients met the criteria and were included. The median follow-up was 24.4 mo (range, 1.4–53.5). The median time between first-course therapy cessation and pembrolizumab retreatment was 10.7 mo (1.0–36.3). Twenty patients (41%) had an objective response with pembrolizumab retreatment, 65% of whom had a CR to first-course treatment. The median retreatment duration was 8.3 mo (range, 0.0–13.2); the median duration of response was 14.0 mo (2.1+ to 20.5). From retreatment initiation, the median (95% confidence interval) progression-free survival and overall survival were 9.5 mo (5.6–15.0) and 25.7 mo (21.5–27.5), respectively. Treatment-related adverse events occurred in 45% (grade 3–4: 6%; grade 5: 0%). Data suggest that pembrolizumab retreatment is beneficial and tolerable for some patients with advanced/metastatic urothelial carcinoma who previously had a CR or completed 2 yr of pembrolizumab.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"5 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142867319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life","authors":"Marie-Pier St-Laurent, Bernard Bochner, James Catto, Benjamin J. Davies, Christian Daniel Fankhauser, Tullika Garg, Jill Hamilton-Reeves, Viraj Master, Bente T. Jensen, Susanne V. Lauridsen, Elizabeth Wulff-Burchfield, Sarah P. Psutka","doi":"10.1016/j.eururo.2024.11.026","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.026","url":null,"abstract":"<h3>Background and objective</h3>Treatment burden refers to the overall impact of medical treatments on a patient’s well-being and daily life. Our objective is to evaluate the impact of treatment burden on quality of life (QoL) in patients with genitourinary (GU) malignancies, highlighting the importance of patient-reported outcomes (PROs) in clinical trials to inform treatment decisions and improve patient care.<h3>Methods</h3>We conducted a narrative review of clinical trials focused on GU malignancy (prostate, bladder, and kidney) between January 2000 and June 2024, analyzing related PROs and findings regarding treatment burden.<h3>Key findings and limitations</h3>Recent landmark clinical trials demonstrate significant improvements in overall survival across GU malignancies with novel therapies. However, the reporting of QoL outcomes in these trials is often inadequate, with many lacking comprehensive data or long-term impact. Current publications are increasingly evaluating treatment burden and its impact on patient well-being as a critical outcome, but most clinical trials to date have failed to assess treatment burden across key domains including financial, time and travel, and medication management.<h3>Conclusions and clinical implications</h3>While advancements in treatment have extended longevity in patients with GU malignancies, the treatment burden associated with the receipt of novel agents and its implications for QoL remain inadequately uncharacterized.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"10 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?","authors":"Steven Tisseverasinghe, Marwan Tolba, Fred Saad, Karim Fizazi, Boris Bahoric, Tamim Niazi","doi":"10.1016/j.eururo.2024.12.003","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.12.003","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"1 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}